Echoing last year's hoopla surrounding Inotek Pharmaceuticals Corp.'s progress with trabodenoson, Wall Street cheered the FDA blessing on Ocular Therapeutix Inc.'s phase III plan with OTX-TP (travoprost), a sustained-release punctal plug for glaucoma and ocular hypertension – a program minus any timolol comparator arm.